KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Restructuring Costs (2016 - 2025)

Historic Restructuring Costs for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $286.0 million.

  • Pfizer's Restructuring Costs fell 862.62% to $286.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 7159.39%. This contributed to the annual value of $2.4 billion for FY2024, which is 1780.5% down from last year.
  • Per Pfizer's latest filing, its Restructuring Costs stood at $286.0 million for Q3 2025, which was down 862.62% from -$74.0 million recorded in Q2 2025.
  • In the past 5 years, Pfizer's Restructuring Costs ranged from a high of $2.6 billion in Q4 2023 and a low of -$74.0 million during Q2 2025
  • Over the past 5 years, Pfizer's median Restructuring Costs value was $195.5 million (recorded in 2022), while the average stood at $418.3 million.
  • As far as peak fluctuations go, Pfizer's Restructuring Costs skyrocketed by 1302000.0% in 2021, and later tumbled by 12291.67% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Restructuring Costs stood at $646.0 million in 2021, then plummeted by 69.2% to $199.0 million in 2022, then surged by 1189.45% to $2.6 billion in 2023, then plummeted by 87.8% to $313.0 million in 2024, then fell by 8.63% to $286.0 million in 2025.
  • Its Restructuring Costs was $286.0 million in Q3 2025, compared to -$74.0 million in Q2 2025 and $678.0 million in Q1 2025.